Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MYC | P01106 | 2/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636377 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL16713045 | 0.84 | CSNK2A2 (0.45) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL11801596 | 0.81 | ALDH1A1 (0.48) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL27544752 | 0.81 | CSNK2A2 (0.49) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL31636602 | 0.79 | ABL1 (0.45) | ALDH1A1TSHRCASP1SMN1; SMN2LMNA | |
| SCHEMBL4670497 | 0.79 | TSHR (0.52) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL29041506 | 0.79 | TSHR (0.52) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL3980826 | 0.79 | CYP1A2 (0.42) | ALDH1A1TSHRSMN1; SMN2MYCNR4A1 | |
| SCHEMBL286718 | 0.79 | HAAO (0.42) | ALDH1A1TSHRTDP1MYCLMNA | |
| SCHEMBL1468068 | 0.78 | GABRA1 (0.43) | ALDH1A1TSHRSMN1; SMN2CYP1A2CLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110312711-A | Heterocyclic compound and its application method as RAS inhibitor | 亚瑞克西斯制药公司 | 2019-10-08 | — | — | CN | disclosed |
| EP-2139843-B1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2139843-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | Amgen, Inc (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008130514-A1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ALDH1A1 1149/4885TSHR 740/4885TP53 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.